lisdexamfetamine Side Effects
Also known as: Vyvanse
Analysis of 5,840 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
5,840
Death-Related
208
3.6% of reports
Hospitalizations
1,746
29.9% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 208 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 95 |
| TOXICITY TO VARIOUS AGENTS | 55 |
| CARDIO-RESPIRATORY ARREST | 38 |
| DEATH | 29 |
| CARDIAC ARREST | 23 |
| RESPIRATORY ARREST | 19 |
| HYPOTENSION | 13 |
| COMA | 12 |
| SUSPECTED SUICIDE | 12 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 10 |
| METABOLIC ACIDOSIS | 9 |
| RESPIRATORY DEPRESSION | 9 |
| ANION GAP | 7 |
| CIRCULATORY COLLAPSE | 6 |
| SEIZURE | 6 |
| ADRENERGIC SYNDROME | 5 |
| HYPERTHERMIA | 5 |
| AGGRESSION | 4 |
| AGITATION | 4 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | 4 |
Reactions in Hospitalization Reports
Top reactions in 1,746 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| INTENTIONAL OVERDOSE | 895 |
| INTENTIONAL SELF-INJURY | 830 |
| DRUG INTERACTION | 105 |
| TOXICITY TO VARIOUS AGENTS | 95 |
| SUICIDE ATTEMPT | 77 |
| DRUG INEFFECTIVE | 66 |
| AGITATION | 59 |
| OVERDOSE | 54 |
| SEROTONIN SYNDROME | 48 |
| TACHYCARDIA | 47 |
| VOMITING | 46 |
| NAUSEA | 45 |
| OFF LABEL USE | 45 |
| HYPOTENSION | 43 |
| ANXIETY | 42 |
| CARDIOGENIC SHOCK | 41 |
| HEADACHE | 41 |
| HYPERHIDROSIS | 39 |
| SUICIDAL IDEATION | 37 |
| DEPRESSION | 33 |
Nearby — Related Medications
What the FAERS Data Reveals About lisdexamfetamine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 5,840 voluntary reports linked to lisdexamfetamine and its brand equivalents (Vyvanse), spanning 2007 through 2025. Of those, 208 (3.6%) listed death as an outcome and 1,746 (29.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 38% male; age distribution skews toward 18-44, with 1,589 reports in that bracket. The single most reported reaction is intentional overdose with 1,068 submissions, followed by intentional self-injury and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.